1. Scrip
  2. >>Therapy Areas
  3. >>Anti-infective

Biogen Backs Down From M&A

 
• By Lisa LaMotta

Biogen Inc. wouldn't acknowledge rumors that it plans to sell its hemophilia business, but CEO George Scangos told analysts during a first quarter earnings call that the big biotech will be focusing on "cost control" and keeping its head down.

Biogen Inc. wouldn't acknowledge rumors that it plans to sell its hemophilia business, but CEO George Scangos told analysts during a first quarter earnings call that the big biotech will be focusing on "cost control" and keeping its head down.

"For the remainder of the year, we are focused on three areas: careful control of our costs, maximizing our revenues,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anti-infective

In Brief: Gilead HIV Trials On Hold Over Safety Signal

 
• By Sushmita Panda

The FDA has paused Gilead’s HIV trials of GS-1720 and GS-4182 over safety concerns. The company’s upcoming PrEP PDUFA looks to be unaffected.

In Brief: PolyPid’s D-PLEX100 Aces Phase III Trial, US Partner, Submission Eyed

 
• By Sushmita Panda

PolyPid's D-PLEX100 meets Phase III endpoints this time around, significantly reducing surgical point infections in abdominal colorectal surgery, and is set for a US approval submission early next year.

With ACIP Upheaval, Merck & Co. Among Those Left In A Lurch

 
• By Jessica Merrill and Bridget Silverman

Merck’s newly approved Enflonsia for RSV is one of the products that was expected to be recommended for use by the CDC advisory committee in June.

Stock Watch: On Q1 Vaccine Sales And Measles Outbreaks

 
• By Andy Smith

A recent study suggested that measles could become endemic in the US due to low vaccination rates. However, first-quarter vaccine sales offered a more nuanced picture.

More from Therapy Areas

With ACIP Upheaval, Merck & Co. Among Those Left In A Lurch

 
• By Jessica Merrill and Bridget Silverman

Merck’s newly approved Enflonsia for RSV is one of the products that was expected to be recommended for use by the CDC advisory committee in June.

Stock Watch: On Q1 Vaccine Sales And Measles Outbreaks

 
• By Andy Smith

A recent study suggested that measles could become endemic in the US due to low vaccination rates. However, first-quarter vaccine sales offered a more nuanced picture.

Metsera’s Amylin Analog Stars In Obesity Phase I

 
• By Joseph Haas

Intended as obesity monotherapy and for combination with the firm’s GLP-1 analog, MET-0233i showed best-in-class efficacy with placebo-like tolerability at low doses.